Jump to content

Talk:Roivant Sciences

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by FinalFrontier.003 (talk | contribs) at 06:54, 27 January 2019 (new edit request). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

WikiProject iconCompanies Unassessed
WikiProject iconThis article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles
???This article has not yet received a rating on Wikipedia's content assessment scale.
???This article has not yet received a rating on the project's importance scale.
WikiProject Companies To-do:
Here are some tasks awaiting attention:

Possible Edits

I have a COI with the company , but would like to suggest some factual edits/corrections below. Thanks!

1. There is no comma in “Roivant Sciences, Ltd.” it’s just “Roivant Sciences Ltd.” Source: https://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex1011.htm

2. A small grammar correction: It should be “the company’s subsidiaries” not “the companies subsidiaries”

3. There is now a new logo which is on the website and image is here: https://static1.squarespace.com/static/5710e74360b5e95e7434951a/t/58c01b61f7e0abb09ddbdad9/1488984934768/

Also, a lot has changed at the company recently so wanted to include some recent news that might be helpful when editing this page moving forward.

1. Topline data from MINDSET is slated to read out in September. Source: https://www.statnews.com/2017/04/10/axovant-new-ceo-david-hung/

2. Enzyvant developing a therapy for Complete DiGeorge Syndrome. Sources: http://www.dukechronicle.com/article/2017/03/pharmaceutical-company-roivant-sciences-collaborates-with-duke-community-in-drug-research and http://medcitynews.com/2017/04/enzyvant-regenerative-medicine-advanced-therapy-rmat-designation/ and https://endpts.com/ramaswamys-enzyvant-scores-a-double-barreled-fda-commitment-to-help-hustle-a-rare-disease-drug-through-its-bla/

3. Relugolix has generate positive Phase 2 trial data for both uterine fibroids and endometriosis-associated pain. Sources: https://endometriosisnews.com/2017/05/22/myovant-presenta-positive-phase-2-results-relugolix-endometriosis-pain/ and http://www.fiercebiotech.com/biotech/myovant-showcases-positive-relugolix-data-will-pfizer-swoop

4. Dermavant purchased the topical rights to cerdulatinib, a Syk/JAK inhibitor, from Portola Pharmaceuticals. It is also advancing a PDE4 inhibitor in-licensed from Eisai. Source: https://endpts.com/is-biopharmas-midas-man-vivek-ramaswamy-building-a-new-ipo-vehicle-with-dermavant-deal/

Thanks 50.75.206.4 (talk) 20:10, 23 May 2017 (UTC)[reply]

Will fix the typos. If the company wants to upload its logo to the commons, the link to do that is here. Make sure who ever does it grants the proper license.
With respect to 1 and 3 - we do not present content about health (like early clinical trial results) based on those kind of sources and we do not care about the timing of release of clinical trial data. This is an encyclopedia not the company's website or some investor board. I will look at items 2 and 4. Jytdog (talk) 20:15, 23 May 2017 (UTC)[reply]

Some corrections/additions to consider

I have a COI with the company, but would like to give some factual corrections/additions below. Thank you!


1. Roivant launched a new subsidiary, Urovant, on June 6, 2017. That company is focused on urologic diseases and its initial drug will be developed for overactive bladder (OAB). Sources: http://www.fiercebiotech.com/biotech/roivant-launches-urovant-phase-3-merck-med and http://fortune.com/2017/06/06/biotech-merck-ramaswamy/ and https://endpts.com/ramaswamy-notches-his-5th-biotech-startup-in-3-years-after-inking-a-deal-with-merck-for-phiii-urology-drug/

2. Two errors on Enzyvant bullet: RVT-802 is being developed for “complete DiGeorge Syndrome” (as opposed to standard “DiGeorge Syndrome”), and the treatment involves “thymus tissue,” not "thyroid tissue” as the article current states. Source: http://medcitynews.com/2017/04/enzyvant-regenerative-medicine-advanced-therapy-rmat-designation/?rf=1

3. For Axovant bullet: intepirdine is being developed for Dementia with Lewy Bodies (DLB) in addition to Alzheimer’s disease (minor point, but it is “Alzheimer’s” disease not “Alzheimers” disease). Sources: http://www.wkyc.com/news/health/lewy-body-dementia-second-most-common-form-of-neurodegenerative-dementia-behind-alzheimers/315225308 and http://www.newsobserver.com/news/local/community/chapel-hill-news/article130991774.html The second article also notes that Axovant is also sponsoring Phase 2 trials looking at whether another drug in its pipeline, nelotanserin, can safely and effectively treat visual hallucinations for patients with with Lewy Body Dementia and REM sleep disorders for patients with DLB. Additional source: http://www.fiercebiotech.com/biotech/early-win-means-phase-3-test-way-for-axovant-s-dementia-drug

4. For Myovant bullet: Myovant does not have a “worldwide license” for relugolix, it has a global license *excluding Japan and certain other Asian countries” (those rights are retained by Takeda). Sources: http://www.fiercebiotech.com/biotech/myovant-showcases-positive-relugolix-data-will-pfizer-swoop and https://www.forbes.com/sites/nathanvardi/2016/10/27/the-woman-at-the-center-of-the-biggest-biotech-ipo-of-the-year/#3f2cbff06b08 and http://www.bioworld.com/content/roivants-myovant-sciences-files-173m-ipo-fund-its-phase-iii-ready-asset

5. For Dermavant bullet: Dermavant has three drugs in development, not two. In addition to the two mentioned, there is an oral caspase-1 inhibitor (RVT-201). The available external sources are admittedly not great, but it is inaccurate to state “As of December 2016 it had two drug candidates” since it already had three at that time. Sources: http://adisinsight.springer.com/drugs/800047675 and http://www.biospace.com/News/dermavant-sciences-announces-licensing-of-topical/442576 (under “About Dermavant Sciences”).

6. Roivant’s new logo can be found here:

new Roivant logo


50.75.206.4 (talk) 13:34, 15 June 2017 (UTC)[reply]

Wikipedia is not going to be a blow-by-blow update to the various companies' pipelines - that is what their websites are for. I will go back over this and remove some detail so you can stop wasting your time (and ours) with pipeline updates. I fixed the thymus error, thanks for pointing that out. More anon. Jytdog (talk) 13:42, 15 June 2017 (UTC)[reply]
information Note: Marked as partial. jd22292 (Jalen D. Folf) (talk) 19:16, 11 July 2017 (UTC)[reply]



Additions

I have a COI, but wanted to see if someone could add in two things. Thanks

1. Roivant launched a new subsidiary, Urovant, on June 6, 2017. That company is focused on urologic diseases and its initial drug will be developed for overactive bladder (OAB). Sources: http://www.fiercebiotech.com/biotech/roivant-launches-urovant-phase-3-merck-med http://fortune.com/2017/06/06/biotech-merck-ramaswamy/ https://endpts.com/ramaswamy-notches-his-5th-biotech-startup-in-3-years-after-inking-a-deal-with-merck-for-phiii-urology-drug/ http://www.pharmaceutical-technology.com/news/newsroivant-forms-new-subsidiary-to-develop-urology-therapies-5836970

2. Could we add the CEOs of Roivant’s subsidiaries: Enzyvant: Alvin Shih Source: https://techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Myovant CEO: Lynn Seely Source: https://techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Axovant: David Hung Source: https://www.wsj.com/articles/the-400-million-man-1491838810 Dermavant: Jackie Fouse Source: http://fortune.com/2017/07/10/biotech-celgene-roivant-ceo/

207.38.201.53 (talk) 12:20, 6 August 2017 (UTC)[reply]

Did the urovant thing; the CEOs are UNDUE here. 01:38, 7 August 2017 (UTC)


Another addition for consideration:

Could we also add Datavant to the subsidiaries section? Datavant is a new technology-focused subsidiary aimed at using artifical intelligence (AI) to unlock insights in health care datasets. Datavant is the first company in the Roivant family to operate outside of traditional biopharmaceutical development.

Sources: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/?ncid=rss and https://www.wired.com/story/softbank-invests-roivant/ 50.75.206.4 (talk) 16:08, 24 August 2017 (UTC)[reply]

Both of those refs talk about plans, not about Datavant actually being created already. Jytdog (talk) 21:04, 24 August 2017 (UTC)[reply]
Here is another article that points to the launch of Datavant including its new CEO Travis May. Source: https://endpts.com/tech-maven-travis-may-takes-the-helm-of-roivants-data-mining-startup/ 50.75.206.4 (talk) 15:34, 2 October 2017 (UTC)[reply]

Updates

I have a COI with the company but I noticed the article is out of date and wanted to suggest a series of edits to be implemented. Thank you.

1. Roivant licenses more than “late-stage” drug candidates (see Genevant, Axovant gene therapy deals below), so more accurate to say “a company that in-licenses investigational drugs and develops them through subsidiaries.”

2. The company and its affiliates now have offices in:

a. San Francisco, C.A. Source: https://www.xconomy.com/national/2018/01/08/axovant-neuro-drug-stumbles-and-falls-in-phase-2-shares-drop-50/

b. San Diego, C.A. Source: https://www.fiercebiotech.com/biotech/roivant-launches-lung-focused-respivant-phase-2-ipf-drug

c. Irvine, C.A. Source: https://www.fiercebiotech.com/biotech/urovant-poaches-allergan-urology-head-as-new-cmo

d. Brisbane, C.A. Source: http://www.finsmes.com/2017/08/roivant-sciences-raises-1-1-billion-in-equity-funding.html

e. Cambridge, M.A. Source: https://www.forbes.com/sites/matthewherper/2018/07/09/vivek-ramaswamys-enzyvant-asks-fda-to-approve-treatment-for-dying-babies/#6fa8c2211007

f. China (Beijing and Shanghai). Source: https://endpts.com/vivek-ramaswamy-strikes-again-this-time-launching-a-beijing-based-biotech-player-with-a-pipeline/

g. Canada (Vancouver) Source: https://www.biospace.com/article/another-notch-on-the-belt-as-ramaswamy-launches-genevant/

3. New subsidiary launched: Datavant. Aims to “de-silo different data sets across healthcare.” Source: https://endpts.com/what-do-you-get-when-you-integrate-healthcare-data-from-multiple-sources-into-one-comprehensive-global-package-travis-may-says-hes-on-track-to-find-out/

4. New subsidiary launched: Sinovant “aimed at developing innovative treatments for some of China’s most pressing medical concerns.” Launched with a pipeline of 11 investigational biopharmaceutical products for Greater China and other Asian markets, including four therapies suitable for Phase III clinical trial application or registration in China. Source: https://www.biospace.com/article/roivant-launches-new-china-based-startup-sinovant-sciences/

5. New subsidiary launched: Respivant “built around an inhaled drug for treating chronic cough in patients with idiopathic pulmonary fibrosis.” Source: https://www.fiercebiotech.com/biotech/roivant-launches-lung-focused-respivant-phase-2-ipf-drug

6. New subsidiary launched: Genevant “working on a range of RNA-based therapeutics backed by Arbutus’ proprietary lipid nanoparticle and ligand conjugate delivery technologies.” Source: https://endpts.com/vivek-ramaswamy-is-diving-into-rna-launching-a-new-biotech-with-arbutus-and-a-team-of-vets/

7. New subsidiary launched: Metavant a “cardiometabolic disease startup” which holds rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker. Source: https://www.fiercebiotech.com/biotech/roivant-licenses-ligand-diabetes-drug-founds-metavant-as-push-into-cardiometabolic-diseases

8. New subsidiary launched: Immunovant, built around “a fully human monoclonal antibody targeting the neonatal Fc receptor.” Source: https://www.biospace.com/article/roivant-taps-genentech-veteran-as-operating-chair-ahead-of-pipeline-day/

9. New subsidiary launched: Altavant, built around “a possible treatment for pulmonary arterial hypertension and other indications.” Source: https://www.biospace.com/article/big-shakeup-and-restructuring-at-vivek-ramaswamy-s-roivant-companies/

10. After discontinuing intepirdine, Axovant has licensed several investigational gene therapies for Parkinson’s disease, oculopharyngeal muscular dystrophy, and other conditions. Source: https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/; https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/

11. Add “biopharmaceutical” to industry listing as subsidiary companies such as Genevant and Immunovant are operating in that space (i.e. biotech rather than conventional pharmaceutical)

12. Update leadership:

a. Add: Myrtle Potter, Dr. Frank Torti, Adele Gulfo, Sam Azoulay, Ben Zimmer, Allen Waxman. Source: https://endpts.com/genentech-vet-myrtle-potter-takes-a-leading-role-in-vivek-ramaswamys-fast-moving-vant-ops/; https://www.fiercebiotech.com/biotech/roivant-appoints-nea-partner-frank-torti-as-overseer-its-vant-subsidiaries; https://www.fiercebiotech.com/biotech/ex-pfizer-execs-join-roivant-s-c-suite; https://www.biospace.com/article/big-shakeup-and-restructuring-at-vivek-ramaswamy-s-roivant-companies/; https://endpts.com/lundbeck-ceo-bags-20m-bonus-jumping-ship-for-teva-helm/

b. Remove: Dr. Lawrence Friedhoff, William Symonds, Marianne Romeo (employed but not senior leadership and not listed in the cited article)

13. Financing history (if including SoftBank might make sense to list earlier rounds):

a. May 2014 seed round - $93 million lead by QVT Financial, included Dexcel Pharma. Source: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/;

b. December 2015 PE/Growth round - $500 million lead by Viking Global. Source: https://www.forbes.com/sites/nathanvardi/2016/07/13/billionaire-andreas-halvorsens-hedge-fund-backs-private-biotech-roivant-sciences/#5fa85b892455

c. August 2017 PE/Growth round - $1.1 billion lead by Softbank Vision Fund, with participation from Founders Fund. Source: https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/

14. In June 2018 Roivant laid off 67 employees, not 70. source: https://www.fiercebiotech.com/roivant-lays-off-staff-reassigns-others-major-reshuffle

15. Add in the logo picture that I’ve uploaded to wiki commons linked here: https://commons.wikimedia.org/wiki/File:Roivant_Logo.png

File:Roivant Logo.png
company logo

— Preceding unsigned comment added by 136.24.120.116 (talk) 22:50, 12 October 2018 (UTC)[reply]

Update Requests

I've recently been asked by Roivant Sciences to look over their page and to try to get their recent edit requests implemented. I'm hoping that these requests can be implemented by the many active editors I see on the page and I'm certainly open for any discussions about making this page more accurate and up-to-date. Thank you for any help with this project! FinalFrontier.003 (talk) 10:36, 31 October 2018 (UTC)[reply]

Extended content
  • Current section text: Roivant has operations in the U.S. (Durham, N.C., and New York City), Switzerland, and Bermuda.
  • Proposed section text: Roivant and its subsidiaries have operations in San Francisco[1], San Diego, Irvine[2] and Brisbane[3], California; Cambridge, Massachusetts[4]; Durham, North Carolina; Beijing and Shanghai,China[5] and Vancouver, Canada. [6]


  • Current section text: The company's leadership includes Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) and Aciphex (rabeprazole), William Symonds, who led the development of Sovaldi (sofosbuvir), Dr. Mayukh Sukhatme, Matthew Gline, Marianne Romeo and Alan Roemer.[1]
  • Proposed section text: The company's leadership includes Dr. Mayukh Sukhatme, Matthew Gline, Alan Roemer,[1] Myrtle Potter[7], Dr. Frank Torti[8], Adele Gulfo, Sam Azoulay[9], Ben Zimmer[10] and Allen Waxman.[11]


  • Proposed additional text: After this sentence ("On 11th August the company announced that they had raised $1.1 billion equity investment led by the SoftBank Vision Fund.") add this information: In May of 2014 they raised $93 million in a seed round led by QVT Financial which included Dexcel Pharma.[12] In December 2015 they had a PE/Growth round of $500 million led by Viking Global.[13] Then, in August 2017 they had a PE/Growth round of $1.1 billion led by Softbank Vision Fund, with participation from Founders Fund. [12]


  • Proposed additional text: At the end of the article, I'd like to add to the subsidiaries with this information about new subsidiaries:
•Datavant is a technology-focused subsidiary aimed at using artificial intelligence (AI) to find insights in health care datasets. Datavant is the first company in the Roivant family to operate outside of traditional biopharmaceutical development. [14]
•Sinovant Sciences launched in 2018 to develop treatments for difficult medical issues in China. They started with 11 investigational biopharmaceutical products that will be used for Greater China and other Asian markets.[15]
•Respivant Sciences launched in 2018 with an inhaled drug that treats chronic cough in patients who have idiopathic pulmonary fibrosis.[16]
•Genevant Sciences was created to work on many RNA-based therapeutics that are backed by Arbutus’ “proprietary lipid nanoparticle and ligand conjugate delivery technologies.” [17]
•Metavant is a “cardiometabolic disease startup” which has the rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker.[18]
•Immunovant was launched in July 2018 to focus on RVT-1401 and its potential to treat IgG-mediated autoimmune diseases.[19]
•Altavant Sciences was launched around RVT-1201 to evaluate the effectiveness of its use as a treatment for pulmonary arterial hypertension.[20]

References

  1. ^ a b Vinluan, Frank. "Axovant Neuro Drug Stumbles and Falls in Phase 2, Shares Drop 50%". Xconomy. Retrieved 31 October 2018.
  2. ^ Hale, Conor. "Roivant launches lung-focused Respivant with phase 2 IPF drug". Fierce Biotech. Retrieved 31 October 2018.
  3. ^ "Roivant Sciences Raises $1.1 Billion in Equity Funding". FinsSMEs. Retrieved 31 October 2018.
  4. ^ Herper, Matthew. "Vivek Ramaswamy's Enzyvant Asks FDA To Approve Treatment For Dying Babies". Forbes. Retrieved 31 October 2018.
  5. ^ Carroll, John. "Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline". Endpoints News. Retrieved 31 October 2018.
  6. ^ Keown, Alex. "Another Notch on the Belt as Ramaswamy Launches Genevant". Biospace. Retrieved 31 October 2018.
  7. ^ Tong, Amber. "Genentech vet Myrtle Potter takes a leading role in Vivek Ramaswamy's fast-moving Vant ops". Endpoints News. Retrieved 31 October 2018.
  8. ^ Hale, Conor. "Roivant appoints NEA partner Torti to oversee its 'vant' subsidiaries". Fierce Biotech. Retrieved 31 October 2018.
  9. ^ Al Idrus, Amirah. "Biotech Ex-Pfizer executives join Roivant's C-suite". Fierce Biotech. Retrieved 31 October 2018.
  10. ^ Terry, Mark. "Big Shakeup and Restructuring at Vivek Ramaswamy's Roivant Companies". BioSpace. Retrieved 31 October 2018.
  11. ^ Shakoor, Shehla. "Lundbeck CEO bags $20M bonus jumping ship for Teva helm". Endpoints News. Retrieved 31 October 2018.
  12. ^ a b Loizos, Connie. "Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank". TechCrunch. Retrieved 31 October 2018.
  13. ^ Vardi, Nathan. "Billionaire Andreas Halvorsen's Hedge Fund Backs Private Biotech Roivant Sciences". Forbes. Retrieved 31 October 2018.
  14. ^ Carroll, John. "Tech maven Travis May takes the helm of Roivant's data mining startup". EndPoints. Retrieved 31 October 2018.
  15. ^ Keown, Alex. "Roivant Launches New China-Based Startup Sinovant Sciences". BioSpace. Retrieved 31 October 2018.
  16. ^ Hale, Conor. "Roivant launches lung-focused Respivant with phase 2 IPF drug". Fierce Biotech. Retrieved 31 October 2018.
  17. ^ Carroll, John. "Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets". Endpoints News. Retrieved 31 October 2018.
  18. ^ Paul Taylor, Nick. "Roivant licenses Ligand diabetes drug, founds Metavant, as push into cardiometabolic diseases gathers pace". FierceBiotech. Retrieved 31 October 2018.
  19. ^ Keown, Alex. "Roivant Taps Genentech Veteran as Operating Chair Ahead of Pipeline Day". BioSpace. Retrieved 31 October 2018.
  20. ^ Terry, Mark. "Big Shakeup and Restructuring at Vivek Ramaswamy's Roivant Companies". BioSpace. Retrieved 31 October 2018.

Editing

I've recently started to implement some of the changes I outlined above as a stated COI editor. I'd love feedback and discourse to help the page stay current and accurate. Thanks! FinalFrontier.003 (talk) 08:11, 6 November 2018 (UTC)[reply]

Edit requests from COI editor

I accidentally made these changes as a COI editor recently and now understand that I need to submit them for review and to have them implemented by all of you. I'd appreciate assistance with these changes and a conversation about what may work and what may not.

Extended content

I'd like this paragraph updated. Reference remains the same.

  • Current text: Urovant was formed in 2017 to complete development of vibegron, a drug candidate for overactive bladder than Merck had developed it through a Phase III trial before deciding to abandon it; Urovant had licensed from Merck.
  • Proposed text: Urovant was formed in 2017 to complete development of vibegron, a drug candidate for overactive bladder that Merck had developed through a Phase III trial before partnering with Kyorin. Urovant later licensed vibegron from Merck.


  • Proposed additional text: At the end of the article, I'd like to add to the subsidiaries with this information about new subsidiaries:
•Respivant Sciences launched in 2018 with an inhaled drug that treats chronic cough in patients who have idiopathic pulmonary fibrosis.[1]
•Genevant Sciences was created to work on RNA-based therapeutics backed by “proprietary lipid nanoparticle and ligand conjugate delivery technologies.” [2]
•Metavant is a “cardiometabolic disease startup” which has the rights to glucagon receptor antagonist and an oral oxidative phosphorylation blocker.[3]
•Immunovant was launched in July 2018 to focus on RVT-1401 and its potential to treat IgG-mediated autoimmune diseases.[4]
•Altavant Sciences was launched around RVT-1201 to evaluate the effectiveness of its use as a treatment for pulmonary arterial hypertension.[5]

References

  1. ^ Hale, Conor. "Roivant launches lung-focused Respivant with phase 2 IPF drug". Fierce Biotech. Retrieved 31 October 2018.
  2. ^ Carroll, John. "Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets". Endpoints News. Retrieved 31 October 2018.
  3. ^ Paul Taylor, Nick. "Roivant licenses Ligand diabetes drug, founds Metavant, as push into cardiometabolic diseases gathers pace". FierceBiotech. Retrieved 31 October 2018.
  4. ^ Keown, Alex. "Roivant Taps Genentech Veteran as Operating Chair Ahead of Pipeline Day". BioSpace. Retrieved 31 October 2018.
  5. ^ Terry, Mark. "Big Shakeup and Restructuring at Vivek Ramaswamy's Roivant Companies". BioSpace. Retrieved 31 October 2018.

FinalFrontier.003 (talk) 07:43, 14 November 2018 (UTC)[reply]

Reply 14-NOV-2018

  Edit request partially implemented  

  1. Green tickY The Urovant paragraph was updated.
  2. Red XN The proposed additional text was not added, as it contained unattributed quoted material. Quotes must be properly attributed, per MOS:QUOTE.
plus Additional changes made:
  1. The paragraph concerning Datavent was omitted, as its text was insufficiently paraphrased from the source material. All added text must be placed in an editor's own words and phrasing, per WP:CLOSEPARAPHRASE.
  2. The use of they when referring to the company was changed to the company.
  3. The use of Dr. when referring to the company's leadership was omitted, per MOS:DOCTOR.
  4. Punctuation which followed ref notes was moved to precede ref notes, per MOS:PUNCTREF.

Regards,  Spintendo  12:59, 14 November 2018 (UTC)[reply]

Edit requests from COI editor

I’m resubmitting these requests with rewording, being careful not to have unattributed quotes or paraphrased materials from source material. I’ve also asked for a few small wording changes that are new. I appreciate all assistance and feedback on these ideas.

Extended content
  • There are two places where I’d like just a few words changed:
•Current text: Enzyvant was founded to develop therapies for rare diseases. One of its treatments is a version of ceramidase being developed as treatment for Farber disease.[30] Another was licensed from Duke University in 2017 and is a potential treatment for a kind of DiGeorge syndrome…
•Proposed text: Enzyvant was founded to develop therapies for rare diseases. One of its treatments is human acid ceramidase being developed as treatment for Farber disease.[30] Another was licensed from Duke University in January 2017 and is a potential treatment for complete DiGeorge Anomaly…
•Current text: Myovant has a license in some territories for relugolix.
•Proposed text: Myovant has a license outside of Asia for relugolix.
  • Resubmission of text to add to the Wiki article with careful changes so there aren’t unattributed quotes or close paraphrasing.
•Respivant Sciences launched in 2018 with an inhaled drug being developed to treat chronic cough for patients who are already diagnosed with idiopathic pulmonary fibrosis. [1]
•Genevant Sciences was created to work on RNA-based therapeutics. [2]
•Metavant is a startup focusing on cardiometabolic disease. The company has the rights to LGD-6972, a glucagon receptor antagonist, and imeglimin. [3]
•Immunovant was launched in July 2018 to focus on the treatment of IgG-mediated autoimmune diseases. [4]
•Altavant Sciences was launched to focus on a possible future treatment for pulmonary arterial hypertension. [5]
  • Resubmitting text that was taken out for paraphrasing issues:
•Datavant was created to break down silos between healthcare datasets. Datavant is the first of the Roivant subsidiaries that is operating outside of traditional biopharmaceutical development. [6]

References

  1. ^ Hale, Conor. "Roivant launches lung-focused Respivant with phase 2 IPF drug". Fierce Biotech. Retrieved 31 October 2018.
  2. ^ Carroll, John. "Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets". Endpoints News. Retrieved 31 October 2018.
  3. ^ Paul Taylor, Nick. "Roivant licenses Ligand diabetes drug, founds Metavant, as push into cardiometabolic diseases gathers pace". FierceBiotech. Retrieved 31 October 2018.
  4. ^ Keown, Alex. "Roivant Taps Genentech Veteran as Operating Chair Ahead of Pipeline Day". BioSpace. Retrieved 31 October 2018.
  5. ^ Terry, Mark. "Big Shakeup and Restructuring at Vivek Ramaswamy's Roivant Companies". BioSpace. Retrieved 31 October 2018.
  6. ^ Carroll, John. "Tech maven Travis May takes the helm of Roivant's data mining startup". Endpoints News. Retrieved 18 November 2018.

Thanks!FinalFrontier.003 (talk) 07:26, 18 November 2018 (UTC)[reply]

Reply to edit request 20-NOV-2018

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  08:05, 20 November 2018 (UTC)[reply]

Proposal review 20-NOV-2018

Enzyvant was founded to develop therapies for rare diseases. One of its treatments is human acid ceramidase being developed as treatment for Farber disease. Another was licensed from Duke University in January 2017 and is a potential treatment for complete DiGeorge Anomaly...
 Partly approved.[note 1]


Myovant has a license outside of Asia for relugolix.
exclamation mark Clarification needed.[note 2]


Respivant Sciences launched in 2018 with an inhaled drug being developed to treat chronic cough for patients who are already diagnosed with idiopathic pulmonary fibrosis.
exclamation mark Clarification needed.[note 3]


Genevant Sciences was created to work on RNA-based therapeutics.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Metavant is a startup focusing on cardiometabolic disease. The company has the rights to LGD-6972, a glucagon receptor antagonist, and imeglimin.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Immunovant was launched in July 2018 to focus on the treatment of IgG-mediated autoimmune diseases.
 Partly approved.[note 4]


Altavant Sciences was launched to focus on a possible future treatment for pulmonary arterial hypertension.
no Declined.[note 5]


Datavant was created to break down silos between healthcare datasets. Datavant is the first of the Roivant subsidiaries that is operating outside of traditional biopharmaceutical development.
 Partly approved.[note 6]


___________

  1. ^ Even though another editor previously found the claim and accompanying source appropriate and implemented them, asking to place a newly worded version is asking for this new version to be judged on its own merits. Thus, parts of this section of the edit request proposal were approved while other parts were not. The approved part concerns the nomenclature used to describe the agent only (as human acid ceramidase) and does not involve modifying language describing the agent's potentiality as treatment. The unapproved part does concern the drug being described as a "potential treatment for complete DiGeorge syndrome." The existing reference for this claim is a company press release provided to Med City News. A more appropriate reference would be from a secondary source. See WP:MEDRS.
  2. ^ This part of the edit request proposal requires clarification because it is unclear which parts outside of Asia the claim is referring to. Please specify.
  3. ^ This part of the edit request proposal requires clarification because it is unclear from the existing language whether this agent is approved for use or not.
  4. ^ This claim was modified to remove the word treatment.
  5. ^ This part of the edit request proposal was declined because the wording of it deals with a future state of affairs which may or may not be concrete (e.g., possible future treatment). See WP:NOTACRYSTALBALL.
  6. ^ The distinction of "operating outside traditional biopharmaceutical development" was omitted.

Edit request: COI editor

I’m requesting a few more edits as a COI editor and I look forward to your feedback.

Extended content
  • At the end of the intro section, after reference 13, I’m requesting to add
• Since its last funding round in August 2017, Roivant has increased its employees from under 350 to 750. During the same timeframe, the number of therapies has increased from 14 to 34. [1]
  • At the end of the Funding section, I’m requesting to add:
•In 2018 the company had a PE/Growth round of $200 million that was anchored by four new institutional investors: NovaQuest, RTW, a large US insurance company, and another large US asset manager. [2]
  • At the end of the Axovant line, after reference 21, I’d like to add:
•In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica.[3] In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma. [4]
  • At the end of the subsidiary list I’d like to add:
•Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases. [5]

References

  1. ^ Terry, Mark. "Roivant Sciences Raises $200 Million, Bringing Its Valuation to $7 Billion". Bio Space. Retrieved 5 December 2018.
  2. ^ Spalding, Rebecca. "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Retrieved 5 December 2018.
  3. ^ Marques Lopes, Jose. "Axovant Obtains Worldwide License to Develop AXO-Lenti-PD, Potential Parkinson's Gene Therapy". Parkinsons News Today. Retrieved 5 December 2018.
  4. ^ "Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders". Genetic Engineering and Biotechnology News. Retrieved 5 December 2018.
  5. ^ Terry, Mark. "Vivek Ramaswamy's Latest "Vant": Aruvant to Focus on Sickle Cell and Beta-Thalassemia". Biospace. Retrieved 5 December 2018.

Thank you! FinalFrontier.003 (talk) 04:09, 5 December 2018 (UTC)[reply]

Reply to edit request 05-DEC-2018

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  10:55, 5 December 2018 (UTC)[reply]

Proposal review 05-DEC-2018

Since its last funding round in August 2017, Roivant has increased its employees from under 350 to 750. During the same timeframe, the number of therapies has increased from 14 to 34.
exclamation mark  Clarification needed.[note 1]


In 2018 the company had a PE/Growth round of $200 million that was anchored by four new institutional investors: NovaQuest, RTW, a large US insurance company, and another large US asset manager.
 Partly approved.[note 2]


In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica.[3] In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma.
exclamation mark  Clarification needed.[note 3]


Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases.
exclamation mark  Clarification needed.[note 4]


___________

  1. ^ Articles should be based on reliable, published secondary sources and, to a lesser extent, on tertiary sources and primary sources. Guidance suggests not basing entire articles or large passages on primary sources. Despite this, the Roivant Sciences article contains mostly primary sources. To verify the additions in this request, please provide secondary sources which are unconnected to the pharmaceutical industry. See WP:PSTS.
  2. ^ This information was added to the funding section, which has been converted into a bar graph displaying the yearly amounts received from the company's seed rounds. Information on specific yearly investors was omitted, but is still accessible to readers through the provided sources. See WP:NOTEVERYTHING, WP:NOTPROMO.
  3. ^ Secondary sources requested.
  4. ^ Ibid.

Edit request

In my last edit request, I received feedback from @Spintendo: that I needed to find references from outside of the pharmaceutical space. I'm including the sentences I'd like added with the references I've found. Thanks for your help, Spintendo and anyone else who might help me here.

Extended content
  • At the end of the Axovant line, after reference 21, I’d like to add:
•In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica.[1] In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma. [2]
  • At the end of the subsidiary list I’d like to add:
•Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases.[3]

References

  1. ^ Marques Lopes, Jose. "Axovant Obtains Worldwide License to Develop AXO-Lenti-PD, Potential Parkinson's Gene Therapy". Parkinson's News Today. Retrieved 16 December 2018.
  2. ^ Pinto, Diogo. "Axovant Enters Global Licensing Deal with Benitec for Investigational AXO-AAV-OPMD Program to Treat OPMD". Muscular Dystrophy News Today. Retrieved 16 December 2018.
  3. ^ Weingartner, Tana; Merritt, Jennifer. "Children's Hospital Joins Forces With Swiss Company To Combat Sickle Cell Disease". BBC World Service. Retrieved 16 December 2018.

FinalFrontier.003 (talk) 07:12, 16 December 2018 (UTC)[reply]


Reply 16-DEC-2018

  Additional references requested  

  1. The references from Parkinson's News Today and Muscular Dystrophy News Today are not unconnected to the pharmaceutical industry.
  2. The reference labeled BBC World Service is actually a Cincinnati-based NPR affiliate reporting on claims affecting a business, Cincinnati Children’s Hospital Medical Center (CCHMC) which operates in Cincinnati. There exists a connection between the radio station and its listener market on one side and Aruvent on the other, who are subsidiaries of Roivant. Just as local stories in a city have a pull on the reporting resources of a station operating within the same city, this radio station is not independent when it is reporting on a story about a company operating in the same city the radio station operates in.

Please provide secondary sources which are unconnected to either side of the actors involved here — both Roivant / the pharmaceutical industry and CCHMC. Regards,  Spintendo  15:30, 16 December 2018 (UTC)[reply]

Offering other sources

Trying again to hit the nail on the head with the type of references requested by @Spintendo:. I'm including the sentences I'd like added with the references I've found. Thanks for your help, Spintendo, and anyone else who might help me here.

Extended content
  • At the end of the Axovant line, after reference 21, I’d like to add:
•In June 2018, the company licensed exclusive worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica.[1] [2]In July 2018, it licensed exclusive worldwide rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma. [3][4]
  • At the end of the subsidiary list I’d like to add:
•Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases.[5]

References

  1. ^ Flanagan, Christin. "Gene Therapy Deal Helps Double Price of Beaten-Down Biotech Company's Shares". Bloomberg. Retrieved 17 December 2018.
  2. ^ Maurer, Allan. "Axovant Durham arm may see more work from $842M gene-therapy deal". Tech Wire Partners. Retrieved 17 December 2018.
  3. ^ "Axovant, Benitec Gain on Licensing Deal for Gene Therapy". Nasdaq. Retrieved 17 December 2018.
  4. ^ "MBVX Nears D Day, BNTC Soars On AXON Deal, DEPO Catches Eyes, APEN Up 47% YTD". Business Insider. Retrieved 17 December 2018.
  5. ^ J. Brunsman, Barrett. "Cincinnati Children's inks biggest commercialization deal ever (Video)". Cincinatti Business Courier. Retrieved 17 December 2018.

FinalFrontier.003 (talk) 10:00, 17 December 2018 (UTC)[reply]

Reply 18-DEC-2018

  Edit request implemented  

  • Despite the direction to place the first claim "after reference 21", the claim was placed under the same bullet point as other information regarding Axovent, after ref tag number #20.

Regards,  Spintendo  16:13, 18 December 2018 (UTC)[reply]

Request to add one subsidiary

I'd like to request that one sentence be added to the list of subsidiaries.

Extended content
  • Anywhere in the list of sibsidiaries I’d like to add:
Altavant Sciences was formed in June 2018 with a therapeutic focus on pulmonary arterial hypertension.[1][2]

References

  1. ^ Henderson, Jennifer. "Changes and headcount reduction at Roivant, but hiring expected in Durham". Bizjournals. Retrieved 7 January 2019.
  2. ^ Henriques, Carolina. "Roivant Launches Altavant Sciences, a New Company Developing PAH Therapy RVT-1201". Pulmonary Hypertension News. Retrieved 7 January 2019.

FinalFrontier.003 (talk) 09:36, 7 January 2019 (UTC)[reply]

Reply 07-JAN-2019

   Clarification needed  

  • Please clarify what is meant by therapeutic focus, per MOS:IDIOM. As a rule, items which are explainable through brevity may often be clouded by vagueness. Please describe in what way the company focuses on PAH and what it is about that focus that makes the mentioning of its work necessary for the article. This enhanced explanation may help readers who are not familiar with disease states and how companies who treat them describe this attention as a "focusing" of their activities.[a]

Regards,  Spintendo  01:04, 8 January 2019 (UTC)[reply]

Notes

  1. ^ The language of "focusing" is one used by select industries, such as healthcare, but is foreign to many other industries where the term is not used (i.e., a gardener does not "focus on weed extraction", etc.) The meaning should be made more clear to readers.

I'm resubmitting my request to add one sentence. I've tried to clarify what a "therapeutic focus" means. Thanks!

Extended content
  • Anywhere in the list of sibsidiaries I’d like to add:
Altavant Sciences was formed in June 2018 to develop a new treatment for pulmonary arterial hypertension.[1][2]

References

  1. ^ Henderson, Jennifer. "Changes and headcount reduction at Roivant, but hiring expected in Durham". Bizjournals. Retrieved 7 January 2019.
  2. ^ Henriques, Carolina. "Roivant Launches Altavant Sciences, a New Company Developing PAH Therapy RVT-1201". Pulmonary Hypertension News. Retrieved 7 January 2019.

FinalFrontier.003 (talk) 07:37, 10 January 2019 (UTC)[reply]

Reply 10-JAN-2019

  Edit request implemented  

  • Thank you for the change in tone for this claim. By using plain-spoken non-industry preferred language, the claim seems more informational as a news item and less like part of a brochure for the company.
  • The word new as in "new treatment" was omitted per MOS:RELTIME.

Regards,  Spintendo  11:06, 10 January 2019 (UTC)[reply]

Edit request

I'd like to request that one sentence be added to the list of subsidiaries.

Extended content
  • At the end of the list of sibsidiaries I’d like to add:
Alyvant was formed in January 2019 to reduce the cost of commercializing medicines by connecting patient data with physician data.[1][2]

References

  1. ^ Truong, Kevin. "Roivant Sciences launches new Alyvant subsidiary". Med City News. Retrieved 23 January 2019.
  2. ^ Grover, Natalie. "Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'". Endpoints News. Retrieved 23 January 2019.

Thank you! FinalFrontier.003 (talk) 06:57, 23 January 2019 (UTC)[reply]

Reply 23-JAN-2019

   Clarification needed  

  • Extraordinary claims require extraordinary references. "Reducing the cost of commercializing medicines" is just such a claim. Please provide references from reliable secondary and third-party sources.

Regards,  Spintendo  07:15, 23 January 2019 (UTC)[reply]

@Spintendo: I certainly understand what you are saying, but I would argue that this company exists (as we know) and has a plan (which makes readers understand what their purpose is). I offer a few ideas, but the third idea leaves the reader without a clear understanding of the company's purpose. In terms of references (as we've discussed in the past) it's a biotech company and is being written up in biotech, pharmaceutical and medical publications. These are all the available references at this time.
Extended content
  • 1. Alyvant was formed in January 2019 to connect patient data with physician data with the goal of reducing the cost of commercializing medicines.
  • 2. Alyvant was formed in January 2019 to connnect patients with more suitable medications using technology.
  • 3. Alyvant was formed in January 2019 to connect patient and physician data. [1][2]

References

  1. ^ Truong, Kevin. "Roivant Sciences launches new Alyvant subsidiary". Med City News. Retrieved 23 January 2019.
  2. ^ Grover, Natalie. "Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'". Endpoints News. Retrieved 23 January 2019.

Thank you for all of your assistance and input, FinalFrontier.003 (talk) 09:13, 23 January 2019 (UTC)[reply]

Revised edit request

In response to the feedback I received to my last edit request for Roivant Sciences, I have formulated the sentence I would like added in a new way. This is intended to be added at the end of the list of subsidiaries.

Extended content

Here are three suggestions that I'm making. I'd prefer to have the first sentence used, but I've written sentences 2 and 3 as alternatives depending on what the editor finds most acceptable. I don't have any other references to offer at this time. It's a biotech company and is being written up in biotech, pharmaceutical and medical publications.

  • 1. Alyvant was formed in January 2019 to connect patient data with physician data with the goal of reducing the cost of commercializing medicines.

or

  • 2. Alyvant was formed in January 2019 to connnect patients with more suitable medications using technology.

or

  • 3. Alyvant was formed in January 2019 to connect patient and physician data. [1][2]

References

  1. ^ Truong, Kevin. "Roivant Sciences launches new Alyvant subsidiary". Med City News. Retrieved 23 January 2019.
  2. ^ Grover, Natalie. "Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'". Endpoints News. Retrieved 23 January 2019.

Thank you for any assistance you can offer, FinalFrontier.003 (talk) 06:54, 27 January 2019 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Roivant_Sciences&oldid=880404805"